MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression

Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome....

Full description

Saved in:
Bibliographic Details
Published inGynecologic oncology Vol. 143; no. 3; pp. 655 - 663
Main Authors Liao, Yanbin, Deng, Yalan, Liu, Jun, Ye, Zhanying, You, Zeshan, Yao, Shuzhong, He, Shanyang
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.12.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome. miR-760 expression in ovarian cancer cell lines and patient tissues were determined using Real-time PCR. 145 human ovarian cancer tissue samples were analyzed by RT-PCR to investigate the association between miR-760expression and the clinicopathological characteristics of ovarian cancer patients. Functional assays, such as MTT, anchorage-independent growth, colony formation and BRDU assay were used to determine the oncogenic role of miR-760 in human ovarian cancer progression. Furthermore, western blotting and luciferase assay were used to determine the mechanism of miR-760 promotes proliferation in ovarian cancer cells. The expression of miR-760 was markedly upregulated in ovarian cancer cell lines and tissues, and high miR-760 expression was associated with an aggressive phenotype and poor prognosis with ovarian cancer patients. Upregulation of miR-760 promoted, whereas downregulation of miR-760 inhibited the proliferation of ovarian cancer cells in vitro. Additionally, we identified PHLPP2 as a direct target of miR-760, and silencing the expression of PHLPP2 is the essential biological function of miR-760 during ovarian cancer cell proliferation. Finally, we showed a significant correlation between miR-760 and PHLPP2 expression in ovarian cancer tissues. Our findings suggest that miR-760 represents a potential onco-miR and participates in ovarian cancer carcinogenesis, which highlight its potential as a target for ovarian cancer therapy. •MiR-760 was significantly upregulated in ovarian cancer.•Overexpressing miR-760 promoted aggressiveness of ovarian cancer.•MiR-760 promoted ovarian cancer aggressiveness by suppressing PGLPP2 expression.
AbstractList Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome. miR-760 expression in ovarian cancer cell lines and patient tissues were determined using Real-time PCR. 145 human ovarian cancer tissue samples were analyzed by RT-PCR to investigate the association between miR-760expression and the clinicopathological characteristics of ovarian cancer patients. Functional assays, such as MTT, anchorage-independent growth, colony formation and BRDU assay were used to determine the oncogenic role of miR-760 in human ovarian cancer progression. Furthermore, western blotting and luciferase assay were used to determine the mechanism of miR-760 promotes proliferation in ovarian cancer cells. The expression of miR-760 was markedly upregulated in ovarian cancer cell lines and tissues, and high miR-760 expression was associated with an aggressive phenotype and poor prognosis with ovarian cancer patients. Upregulation of miR-760 promoted, whereas downregulation of miR-760 inhibited the proliferation of ovarian cancer cells in vitro. Additionally, we identified PHLPP2 as a direct target of miR-760, and silencing the expression of PHLPP2 is the essential biological function of miR-760 during ovarian cancer cell proliferation. Finally, we showed a significant correlation between miR-760 and PHLPP2 expression in ovarian cancer tissues. Our findings suggest that miR-760 represents a potential onco-miR and participates in ovarian cancer carcinogenesis, which highlight its potential as a target for ovarian cancer therapy.
Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome. miR-760 expression in ovarian cancer cell lines and patient tissues were determined using Real-time PCR. 145 human ovarian cancer tissue samples were analyzed by RT-PCR to investigate the association between miR-760expression and the clinicopathological characteristics of ovarian cancer patients. Functional assays, such as MTT, anchorage-independent growth, colony formation and BRDU assay were used to determine the oncogenic role of miR-760 in human ovarian cancer progression. Furthermore, western blotting and luciferase assay were used to determine the mechanism of miR-760 promotes proliferation in ovarian cancer cells. The expression of miR-760 was markedly upregulated in ovarian cancer cell lines and tissues, and high miR-760 expression was associated with an aggressive phenotype and poor prognosis with ovarian cancer patients. Upregulation of miR-760 promoted, whereas downregulation of miR-760 inhibited the proliferation of ovarian cancer cells in vitro. Additionally, we identified PHLPP2 as a direct target of miR-760, and silencing the expression of PHLPP2 is the essential biological function of miR-760 during ovarian cancer cell proliferation. Finally, we showed a significant correlation between miR-760 and PHLPP2 expression in ovarian cancer tissues. Our findings suggest that miR-760 represents a potential onco-miR and participates in ovarian cancer carcinogenesis, which highlight its potential as a target for ovarian cancer therapy. •MiR-760 was significantly upregulated in ovarian cancer.•Overexpressing miR-760 promoted aggressiveness of ovarian cancer.•MiR-760 promoted ovarian cancer aggressiveness by suppressing PGLPP2 expression.
Abstract Objective Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome. Methods miR-760 expression in ovarian cancer cell lines and patient tissues were determined using Real-time PCR. 145 human ovarian cancer tissue samples were analyzed by RT-PCR to investigate the association between miR-760expression and the clinicopathological characteristics of ovarian cancer patients. Functional assays, such as MTT, anchorage-independent growth, colony formation and BRDU assay were used to determine the oncogenic role of miR-760 in human ovarian cancer progression. Furthermore, western blotting and luciferase assay were used to determine the mechanism of miR-760 promotes proliferation in ovarian cancer cells. Result The expression of miR-760 was markedly upregulated in ovarian cancer cell lines and tissues, and high miR-760 expression was associated with an aggressive phenotype and poor prognosis with ovarian cancer patients. Upregulation of miR-760 promoted, whereas downregulation of miR-760 inhibited the proliferation of ovarian cancer cells in vitro. Additionally, we identified PHLPP2 as a direct target of miR-760, and silencing the expression of PHLPP2 is the essential biological function of miR-760 during ovarian cancer cell proliferation. Finally, we showed a significant correlation between miR-760 and PHLPP2 expression in ovarian cancer tissues. Conclusion Our findings suggest that miR-760 represents a potential onco-miR and participates in ovarian cancer carcinogenesis, which highlight its potential as a target for ovarian cancer therapy.
Author He, Shanyang
You, Zeshan
Deng, Yalan
Yao, Shuzhong
Ye, Zhanying
Liu, Jun
Liao, Yanbin
Author_xml – sequence: 1
  givenname: Yanbin
  surname: Liao
  fullname: Liao, Yanbin
  organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China
– sequence: 2
  givenname: Yalan
  surname: Deng
  fullname: Deng, Yalan
  organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China
– sequence: 3
  givenname: Jun
  surname: Liu
  fullname: Liu, Jun
  organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China
– sequence: 4
  givenname: Zhanying
  surname: Ye
  fullname: Ye, Zhanying
  organization: Department of Function, Hospital of Dongkeng, Dongguan 523451,PR China
– sequence: 5
  givenname: Zeshan
  surname: You
  fullname: You, Zeshan
  organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China
– sequence: 6
  givenname: Shuzhong
  surname: Yao
  fullname: Yao, Shuzhong
  organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China
– sequence: 7
  givenname: Shanyang
  surname: He
  fullname: He, Shanyang
  email: hsy5g777@sina.com
  organization: Department of Obstetrics and Gynecology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510700, PR China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27726922$$D View this record in MEDLINE/PubMed
BookMark eNqFke1qFDEUhoNU7LZ6BYLMDcx4ksxkJoiClGqFFRc_wH8hk5wpWWeTJZmtzt2b6VqEgvZXvt7nPTnvOSMnPngk5DmFigIVL7fVfD37ULF8qEBWQOERWVGQTSm6Rp6QFYCEsmNNd0rOUtoCAAfKnpBT1rZMSMZWZPjoPpetgCLcYMRf-4gpueCLfQy7MGFaNqMbMOppuXY-C3V02hdGe4Ox6OfChp8-4vVhPGrCUGyu1psNK_76PSWPBz0mfPZnPSff3l1-vbgq15_ef7h4uy5NLcRUGqt7Dpz1LUgrrUEhuW21NU3N626wLe9RtHLotdEDz4-MN8JaajqKdRbwc_Li6Ls_9Du0ah_dTsdZ3TWcBfIoMDGkFHFQxk23_56idqOioJZw1VbdhquWcBVIlcPNLL_H3tn_n3p9pDD3feMwqmQc5uysi2gmZYN7gH9zjzej887o8QfOmLbhEH2OVFGVmAL1ZRn6MnMqOK0pfM8Gr_5t8GD5337zv6o
CitedBy_id crossref_primary_10_1177_11769343211041379
crossref_primary_10_1155_2022_2960773
crossref_primary_10_1002_cam4_2866
crossref_primary_10_1016_j_bbrc_2019_03_009
crossref_primary_10_3892_mmr_2019_10008
crossref_primary_10_1016_j_canlet_2024_217357
crossref_primary_10_1007_s11010_024_05004_1
crossref_primary_10_1101_gad_339317_120
crossref_primary_10_3892_mmr_2017_7814
crossref_primary_10_1016_j_lfs_2020_118337
crossref_primary_10_1016_j_omto_2022_03_004
crossref_primary_10_2147_CMAR_S256670
crossref_primary_10_1074_jbc_M117_809913
crossref_primary_10_2147_CMAR_S352308
crossref_primary_10_1016_j_clinsp_2024_100391
crossref_primary_10_3748_wjg_v25_i45_6619
crossref_primary_10_1080_15548627_2020_1733262
crossref_primary_10_1109_TCBB_2019_2933205
crossref_primary_10_1016_j_placenta_2022_01_013
crossref_primary_10_1111_1759_7714_13196
crossref_primary_10_3389_fphar_2019_01700
crossref_primary_10_3390_cancers13112690
crossref_primary_10_1016_j_ygyno_2017_12_018
crossref_primary_10_3390_ijms22020627
crossref_primary_10_3892_mmr_2019_10775
crossref_primary_10_4103_aja_aja_20_20
crossref_primary_10_1093_bib_bbab264
crossref_primary_10_1016_j_prp_2021_153420
crossref_primary_10_3390_genes13112054
crossref_primary_10_3892_ol_2018_9546
crossref_primary_10_1002_jcb_29540
crossref_primary_10_1007_s10620_021_06876_9
crossref_primary_10_1016_j_gene_2020_144903
crossref_primary_10_3389_fonc_2020_01084
crossref_primary_10_3389_fmed_2022_923275
crossref_primary_10_3233_CBM_190091
crossref_primary_10_1016_j_biopha_2018_01_076
crossref_primary_10_1016_j_gene_2020_144648
crossref_primary_10_1111_jcmm_14071
crossref_primary_10_1038_s41420_022_01236_6
crossref_primary_10_2147_OTT_S240022
crossref_primary_10_3390_cancers13051085
crossref_primary_10_1177_1533033819853237
crossref_primary_10_1007_s11356_017_1138_0
crossref_primary_10_1186_s13046_018_0757_8
crossref_primary_10_1016_j_envpol_2021_117213
Cites_doi 10.3892/br.2013.109
10.1146/annurev-pharmtox-011112-140338
10.2174/18715206113139990116
10.1097/AOG.0000000000000854
10.1007/s13277-016-4900-x
10.2174/1568009611313030001
10.1007/s10549-012-2035-3
10.1158/1078-0432.CCR-12-3186
10.1016/j.biopha.2014.11.028
10.1007/s00125-011-2116-6
10.1007/s13277-015-3445-8
10.1097/IGC.0000000000000007
10.1158/0008-5472.CAN-13-0297
10.1053/j.gastro.2011.10.026
10.1158/2159-8290.CD-ND2013-013
10.1111/j.1471-4159.2010.06609.x
10.18632/oncotarget.6848
10.1016/S0092-8674(04)00045-5
10.1038/nature02871
10.1016/j.molmed.2014.06.005
10.3802/jgo.2015.26.2.155
10.1038/sj.onc.1209100
10.1016/j.devcel.2006.09.009
10.1016/j.molcel.2007.02.017
10.1158/1078-0432.CCR-13-0244
10.1158/1078-0432.CCR-07-4054
10.1016/j.fertnstert.2014.04.024
10.3322/caac.21262
10.1007/s13277-014-2790-3
10.14348/molcells.2014.0157
10.1186/s13048-015-0162-2
10.1046/j.1525-1438.2001.11(suppl.1)sup1003.x
10.1158/1078-0432.CCR-14-2829
10.1007/978-3-319-17121-0_55
10.1016/j.ygyno.2014.07.103
10.1186/s13046-016-0307-1
10.1186/1757-2215-5-8
10.1186/s12885-015-1711-1
ContentType Journal Article
Copyright 2016
Copyright © 2016. Published by Elsevier Inc.
Copyright_xml – notice: 2016
– notice: Copyright © 2016. Published by Elsevier Inc.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1016/j.ygyno.2016.09.010
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE



Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1095-6859
EndPage 663
ExternalDocumentID 27726922
10_1016_j_ygyno_2016_09_010
S009082581631410X
1_s2_0_S009082581631410X
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29I
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQQT
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFGL
ADMUD
ADNMO
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
COF
CS3
DM4
DU5
EBS
EFBJH
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HED
HMK
HMO
HVGLF
HZ~
IH2
IHE
J1W
K-O
KOM
L7B
LG5
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OQ.
OZT
P-8
P-9
P2P
PC.
PH~
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSZ
T5K
UDS
UHS
UV1
WUQ
X7M
XPP
Z5R
ZGI
ZMT
ZU3
ZXP
~G-
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
AAIAV
ABLVK
ABYKQ
AHPSJ
AJBFU
EFLBG
LCYCR
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ID FETCH-LOGICAL-c466t-cdab3032b709d9dce693d7adc54348fd73be679fbacaf36932356dd1c81e448f3
IEDL.DBID .~1
ISSN 0090-8258
IngestDate Thu Apr 03 07:02:54 EDT 2025
Thu Apr 24 23:10:16 EDT 2025
Tue Jul 01 03:07:44 EDT 2025
Fri Feb 23 02:31:06 EST 2024
Tue Feb 25 20:12:37 EST 2025
Tue Aug 26 16:32:53 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords PHLPP2
Proliferation
miR-760
Ovarian cancer
Language English
License Copyright © 2016. Published by Elsevier Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c466t-cdab3032b709d9dce693d7adc54348fd73be679fbacaf36932356dd1c81e448f3
PMID 27726922
PageCount 9
ParticipantIDs pubmed_primary_27726922
crossref_citationtrail_10_1016_j_ygyno_2016_09_010
crossref_primary_10_1016_j_ygyno_2016_09_010
elsevier_sciencedirect_doi_10_1016_j_ygyno_2016_09_010
elsevier_clinicalkeyesjournals_1_s2_0_S009082581631410X
elsevier_clinicalkey_doi_10_1016_j_ygyno_2016_09_010
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-12-01
PublicationDateYYYYMMDD 2016-12-01
PublicationDate_xml – month: 12
  year: 2016
  text: 2016-12-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Gynecologic oncology
PublicationTitleAlternate Gynecol Oncol
PublicationYear 2016
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Menon, Jacobs (bb0020) 2001; 11
Yang, Gu, Zhou, Xiang, Chen (bb0130) 2013; 1
Li, Shi, Ling, Wang, Liu, Wang (bb0065) 2015; 36
Lee, Kim, Bae (bb0145) 2014; 37
Torre, Bray, Siegel, Ferlay, Lortet-Tieulent, Jemal (bb0005) 2015; 65
Testa, Tsichlis (bb0170) 2005; 24
Jiang (bb0180) 2013; 13
Baley, Li (bb0050) 2012; 5
Chang, Bristow (bb0010) 2015; 26
Liu, Qin, Hou, Huang (bb0075) 2015; 36
Lv, Yang, Wang, Xie, Hu, Ye (bb0195) 2015; 15
Li, Zhang, Song, Liao, Jiang (bb0110) 2008; 14
Zhou, Yu, Wang, Li, Jin, Lei (bb0080) 2015; 10
Li, Fang, Liu, Yang (bb0060) 2015; 8
Huang, Pan, Jin, Li, Zhang, Yang (bb0085) 2015; 21
Hayes, Peruzzi, Lawler (bb0125) 2014; 20
Lv, Fu, Shi, Xia, Ji, Xu (bb0140) 2015; 69
Iwaya, Fukagawa, Suzuki, Takahashi, Sawada, Ishibashi (bb0135) 2013; 19
Rajala, Kanan, Anderson (bb0155) 2016; 854
Yan, Jiang, Meng, Xiu, Zong (bb0070) 2016; 35
Cai, Fang, Huang, Li, Yuan, Yang (bb0095) 2013; 73
Wright, Chen, Tergas, Patankar, Burke, Hou (bb0015) 2015; 125
Newton, Trotman (bb0150) 2014; 54
Ambros (bb0045) 2004; 431
Liao, Li, Wang, Wang, He, Ye (bb0100) 2013; 19
Brognard, Sierecki, Gao, Newton (bb0185) 2007; 25
Bartel (bb0040) 2004; 116
Gill, Alex, Navgeet (bb0115) 2016
Santarpia, Qi, Stemke-Hale, Wang, Young, Booser (bb0090) 2012; 134
Kanan, Matsumoto, Song, Sokolov, Anderson, Rajala (bb0165) 2010; 113
Imbar, Eisenberg (bb0055) 2014; 101
Kumar, Bakkum-Gamez, Weaver, McGree, Cliby (bb0025) 2014; 135
Andreozzi, Procopio, Greco, Mannino, Miele, Raciti (bb0160) 2011; 54
Amate, Huchon, Dessapt, Bensaid, Medioni, Le Frere Belda (bb0035) 2013; 23
Smith, Wen, Stevens, Liu, Wang, Gao (bb0190) 2016
Kloosterman, Plasterk (bb0120) 2006; 11
Sylvester, Ayoub (bb0175) 2013; 13
Nitsche, Edderkaoui, Moore, Eibl, Kasahara, Treger (bb0105) 2012; 142
Bender (bb0030) 2013; 3
Lv (10.1016/j.ygyno.2016.09.010_bb0140) 2015; 69
Newton (10.1016/j.ygyno.2016.09.010_bb0150) 2014; 54
Smith (10.1016/j.ygyno.2016.09.010_bb0190) 2016
Bartel (10.1016/j.ygyno.2016.09.010_bb0040) 2004; 116
Lee (10.1016/j.ygyno.2016.09.010_bb0145) 2014; 37
Cai (10.1016/j.ygyno.2016.09.010_bb0095) 2013; 73
Ambros (10.1016/j.ygyno.2016.09.010_bb0045) 2004; 431
Li (10.1016/j.ygyno.2016.09.010_bb0065) 2015; 36
Hayes (10.1016/j.ygyno.2016.09.010_bb0125) 2014; 20
Menon (10.1016/j.ygyno.2016.09.010_bb0020) 2001; 11
Rajala (10.1016/j.ygyno.2016.09.010_bb0155) 2016; 854
Kloosterman (10.1016/j.ygyno.2016.09.010_bb0120) 2006; 11
Jiang (10.1016/j.ygyno.2016.09.010_bb0180) 2013; 13
Andreozzi (10.1016/j.ygyno.2016.09.010_bb0160) 2011; 54
Lv (10.1016/j.ygyno.2016.09.010_bb0195) 2015; 15
Huang (10.1016/j.ygyno.2016.09.010_bb0085) 2015; 21
Nitsche (10.1016/j.ygyno.2016.09.010_bb0105) 2012; 142
Sylvester (10.1016/j.ygyno.2016.09.010_bb0175) 2013; 13
Torre (10.1016/j.ygyno.2016.09.010_bb0005) 2015; 65
Liu (10.1016/j.ygyno.2016.09.010_bb0075) 2015; 36
Testa (10.1016/j.ygyno.2016.09.010_bb0170) 2005; 24
Iwaya (10.1016/j.ygyno.2016.09.010_bb0135) 2013; 19
Zhou (10.1016/j.ygyno.2016.09.010_bb0080) 2015; 10
Santarpia (10.1016/j.ygyno.2016.09.010_bb0090) 2012; 134
Brognard (10.1016/j.ygyno.2016.09.010_bb0185) 2007; 25
Baley (10.1016/j.ygyno.2016.09.010_bb0050) 2012; 5
Li (10.1016/j.ygyno.2016.09.010_bb0060) 2015; 8
Amate (10.1016/j.ygyno.2016.09.010_bb0035) 2013; 23
Liao (10.1016/j.ygyno.2016.09.010_bb0100) 2013; 19
Yan (10.1016/j.ygyno.2016.09.010_bb0070) 2016; 35
Wright (10.1016/j.ygyno.2016.09.010_bb0015) 2015; 125
Kanan (10.1016/j.ygyno.2016.09.010_bb0165) 2010; 113
Chang (10.1016/j.ygyno.2016.09.010_bb0010) 2015; 26
Bender (10.1016/j.ygyno.2016.09.010_bb0030) 2013; 3
Li (10.1016/j.ygyno.2016.09.010_bb0110) 2008; 14
Kumar (10.1016/j.ygyno.2016.09.010_bb0025) 2014; 135
Yang (10.1016/j.ygyno.2016.09.010_bb0130) 2013; 1
Gill (10.1016/j.ygyno.2016.09.010_bb0115) 2016
Imbar (10.1016/j.ygyno.2016.09.010_bb0055) 2014; 101
References_xml – volume: 54
  start-page: 1879
  year: 2011
  end-page: 1887
  ident: bb0160
  article-title: Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance
  publication-title: Diabetologia
– volume: 73
  start-page: 5402
  year: 2013
  end-page: 5415
  ident: bb0095
  article-title: miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer
  publication-title: Cancer Res.
– volume: 116
  start-page: 281
  year: 2004
  end-page: 297
  ident: bb0040
  article-title: MicroRNAs: genomics, biogenesis, mechanism, and function
  publication-title: Cell
– volume: 65
  start-page: 87
  year: 2015
  end-page: 108
  ident: bb0005
  article-title: Global cancer statistics, 2012
  publication-title: CA Cancer J. Clin.
– volume: 23
  start-page: 1590
  year: 2013
  end-page: 1596
  ident: bb0035
  article-title: Ovarian cancer: sites of recurrence
  publication-title: Int. J. Gynecol. Cancer: Official Journal of the International Gynecological Cancer Society
– year: 2016
  ident: bb0190
  article-title: PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells
  publication-title: Oncotarget
– volume: 69
  start-page: 162
  year: 2015
  end-page: 169
  ident: bb0140
  article-title: Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin
  publication-title: Biomedicine & Pharmacotherapy
– volume: 19
  start-page: 4662
  year: 2013
  end-page: 4672
  ident: bb0100
  article-title: microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2
  publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research
– volume: 13
  start-page: 1039
  year: 2013
  end-page: 1047
  ident: bb0175
  article-title: Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy
  publication-title: Anti Cancer Agents Med. Chem.
– volume: 36
  start-page: 1881
  year: 2015
  end-page: 1893
  ident: bb0075
  article-title: MicroRNA-17 promotes normal ovarian cancer cells to cancer stem cells development via suppression of the LKB1-p53-p21/WAF1 pathway
  publication-title: Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine
– volume: 21
  start-page: 3783
  year: 2015
  end-page: 3793
  ident: bb0085
  article-title: PHLPP2 downregulation contributes to lung carcinogenesis following B[
  publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research
– volume: 35
  start-page: 31
  year: 2016
  ident: bb0070
  article-title: MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression
  publication-title: J. Exp. Clin. Cancer Res.: CR.
– volume: 14
  start-page: 3319
  year: 2008
  end-page: 3326
  ident: bb0110
  article-title: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival
  publication-title: Clin. Cancer Res.
– volume: 101
  start-page: 1524
  year: 2014
  end-page: 1530
  ident: bb0055
  article-title: Regulatory role of microRNAs in ovarian function
  publication-title: Fertil. Steril.
– volume: 26
  start-page: 155
  year: 2015
  ident: bb0010
  article-title: Surgical technique of en bloc pelvic resection for advanced ovarian cancer
  publication-title: J. Gynecol. Oncol.
– volume: 25
  start-page: 917
  year: 2007
  end-page: 931
  ident: bb0185
  article-title: PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms
  publication-title: Mol. Cell
– volume: 3
  start-page: OF8
  year: 2013
  ident: bb0030
  article-title: Trials show delayed recurrence in ovarian cancer
  publication-title: Cancer Discovery
– volume: 1
  start-page: 495
  year: 2013
  end-page: 498
  ident: bb0130
  article-title: Serum microRNAs: a new diagnostic method for colorectal cancer
  publication-title: Biomedical Reports
– year: 2016
  ident: bb0115
  article-title: Missing link between microRNA and prostate cancer
  publication-title: Tumour Biol.: The Journal of the International Society for Oncodevelopmental Biology and Medicine
– volume: 20
  start-page: 460
  year: 2014
  end-page: 469
  ident: bb0125
  article-title: MicroRNAs in cancer: biomarkers, functions and therapy
  publication-title: Trends Mol. Med.
– volume: 113
  start-page: 477
  year: 2010
  end-page: 488
  ident: bb0165
  article-title: Serine/threonine kinase akt activation regulates the activity of retinal serine/threonine phosphatases, PHLPP and PHLPPL
  publication-title: J. Neurochem.
– volume: 135
  start-page: 19
  year: 2014
  end-page: 24
  ident: bb0025
  article-title: Impact of obesity on surgical and oncologic outcomes in ovarian cancer
  publication-title: Gynecol. Oncol.
– volume: 36
  start-page: 7277
  year: 2015
  end-page: 7283
  ident: bb0065
  article-title: MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL
  publication-title: Tumour Biol.: The Journal of the International Society for Oncodevelopmental Biology and Medicine
– volume: 854
  start-page: 419
  year: 2016
  end-page: 424
  ident: bb0155
  article-title: Photoreceptor neuroprotection: regulation of Akt activation through serine/threonine phosphatases, PHLPP and PHLPPL
  publication-title: Adv. Exp. Med. Biol.
– volume: 13
  start-page: 233
  year: 2013
  ident: bb0180
  article-title: PI3K/AKT and mTOR/p70S6K1 signaling pathways in human cancer
  publication-title: Curr. Cancer Drug Targets
– volume: 431
  start-page: 350
  year: 2004
  end-page: 355
  ident: bb0045
  article-title: The functions of animal microRNAs
  publication-title: Nature
– volume: 37
  start-page: 620
  year: 2014
  end-page: 627
  ident: bb0145
  article-title: Upregulation of miR-760 and miR-186 is associated with replicative senescence in human lung fibroblast cells
  publication-title: Mol. Cell
– volume: 10
  year: 2015
  ident: bb0080
  article-title: Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma
  publication-title: PLoS One
– volume: 24
  start-page: 7391
  year: 2005
  end-page: 7393
  ident: bb0170
  article-title: AKT signaling in normal and malignant cells
  publication-title: Oncogene
– volume: 134
  start-page: 333
  year: 2012
  end-page: 343
  ident: bb0090
  article-title: Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
  publication-title: Breast Cancer Res. Treat.
– volume: 19
  start-page: 6438
  year: 2013
  end-page: 6449
  ident: bb0135
  article-title: Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer
  publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research
– volume: 15
  start-page: 687
  year: 2015
  ident: bb0195
  article-title: High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma
  publication-title: BMC Cancer
– volume: 142
  start-page: 377
  year: 2012
  end-page: 387
  ident: bb0105
  article-title: The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation
  publication-title: Gastroenterology
– volume: 5
  start-page: 8
  year: 2012
  ident: bb0050
  article-title: MicroRNAs and ovarian function
  publication-title: Journal of Ovarian Research
– volume: 11
  start-page: 3
  year: 2001
  end-page: 6
  ident: bb0020
  article-title: Ovarian cancer screening in the general population: current status
  publication-title: International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society
– volume: 125
  start-page: 1345
  year: 2015
  end-page: 1352
  ident: bb0015
  article-title: Trends in relative survival for ovarian cancer from 1975 to 2011
  publication-title: Obstet. Gynecol.
– volume: 8
  start-page: 51
  year: 2015
  ident: bb0060
  article-title: MicroRNAs in ovarian function and disorders
  publication-title: Journal of Ovarian Research
– volume: 11
  start-page: 441
  year: 2006
  end-page: 450
  ident: bb0120
  article-title: The diverse functions of microRNAs in animal development and disease
  publication-title: Dev. Cell
– volume: 54
  start-page: 537
  year: 2014
  end-page: 558
  ident: bb0150
  article-title: Turning off AKT: PHLPP as a drug target
  publication-title: Annu. Rev. Pharmacol. Toxicol.
– volume: 10
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0080
  article-title: Aberrant expression of PHLPP1 and PHLPP2 correlates with poor prognosis in patients with hypopharyngeal squamous cell carcinoma
  publication-title: PLoS One
– volume: 1
  start-page: 495
  year: 2013
  ident: 10.1016/j.ygyno.2016.09.010_bb0130
  article-title: Serum microRNAs: a new diagnostic method for colorectal cancer
  publication-title: Biomedical Reports
  doi: 10.3892/br.2013.109
– volume: 54
  start-page: 537
  year: 2014
  ident: 10.1016/j.ygyno.2016.09.010_bb0150
  article-title: Turning off AKT: PHLPP as a drug target
  publication-title: Annu. Rev. Pharmacol. Toxicol.
  doi: 10.1146/annurev-pharmtox-011112-140338
– volume: 13
  start-page: 1039
  year: 2013
  ident: 10.1016/j.ygyno.2016.09.010_bb0175
  article-title: Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy
  publication-title: Anti Cancer Agents Med. Chem.
  doi: 10.2174/18715206113139990116
– volume: 125
  start-page: 1345
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0015
  article-title: Trends in relative survival for ovarian cancer from 1975 to 2011
  publication-title: Obstet. Gynecol.
  doi: 10.1097/AOG.0000000000000854
– year: 2016
  ident: 10.1016/j.ygyno.2016.09.010_bb0115
  article-title: Missing link between microRNA and prostate cancer
  publication-title: Tumour Biol.: The Journal of the International Society for Oncodevelopmental Biology and Medicine
  doi: 10.1007/s13277-016-4900-x
– volume: 13
  start-page: 233
  year: 2013
  ident: 10.1016/j.ygyno.2016.09.010_bb0180
  article-title: PI3K/AKT and mTOR/p70S6K1 signaling pathways in human cancer
  publication-title: Curr. Cancer Drug Targets
  doi: 10.2174/1568009611313030001
– volume: 134
  start-page: 333
  year: 2012
  ident: 10.1016/j.ygyno.2016.09.010_bb0090
  article-title: Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-012-2035-3
– volume: 19
  start-page: 6438
  year: 2013
  ident: 10.1016/j.ygyno.2016.09.010_bb0135
  article-title: Contrasting expression patterns of histone mRNA and microRNA 760 in patients with gastric cancer
  publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-12-3186
– volume: 69
  start-page: 162
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0140
  article-title: Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin
  publication-title: Biomedicine & Pharmacotherapy=Biomedecine & Pharmacotherapie
  doi: 10.1016/j.biopha.2014.11.028
– volume: 54
  start-page: 1879
  year: 2011
  ident: 10.1016/j.ygyno.2016.09.010_bb0160
  article-title: Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistance
  publication-title: Diabetologia
  doi: 10.1007/s00125-011-2116-6
– volume: 36
  start-page: 7277
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0065
  article-title: MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL
  publication-title: Tumour Biol.: The Journal of the International Society for Oncodevelopmental Biology and Medicine
  doi: 10.1007/s13277-015-3445-8
– volume: 23
  start-page: 1590
  year: 2013
  ident: 10.1016/j.ygyno.2016.09.010_bb0035
  article-title: Ovarian cancer: sites of recurrence
  publication-title: Int. J. Gynecol. Cancer: Official Journal of the International Gynecological Cancer Society
  doi: 10.1097/IGC.0000000000000007
– volume: 73
  start-page: 5402
  year: 2013
  ident: 10.1016/j.ygyno.2016.09.010_bb0095
  article-title: miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-13-0297
– volume: 142
  start-page: 377
  year: 2012
  ident: 10.1016/j.ygyno.2016.09.010_bb0105
  article-title: The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2011.10.026
– volume: 3
  start-page: OF8
  year: 2013
  ident: 10.1016/j.ygyno.2016.09.010_bb0030
  article-title: Trials show delayed recurrence in ovarian cancer
  publication-title: Cancer Discovery
  doi: 10.1158/2159-8290.CD-ND2013-013
– volume: 113
  start-page: 477
  year: 2010
  ident: 10.1016/j.ygyno.2016.09.010_bb0165
  article-title: Serine/threonine kinase akt activation regulates the activity of retinal serine/threonine phosphatases, PHLPP and PHLPPL
  publication-title: J. Neurochem.
  doi: 10.1111/j.1471-4159.2010.06609.x
– year: 2016
  ident: 10.1016/j.ygyno.2016.09.010_bb0190
  article-title: PHLPP negatively regulates cell motility through inhibition of Akt activity and integrin expression in pancreatic cancer cells
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.6848
– volume: 116
  start-page: 281
  year: 2004
  ident: 10.1016/j.ygyno.2016.09.010_bb0040
  article-title: MicroRNAs: genomics, biogenesis, mechanism, and function
  publication-title: Cell
  doi: 10.1016/S0092-8674(04)00045-5
– volume: 431
  start-page: 350
  year: 2004
  ident: 10.1016/j.ygyno.2016.09.010_bb0045
  article-title: The functions of animal microRNAs
  publication-title: Nature
  doi: 10.1038/nature02871
– volume: 20
  start-page: 460
  year: 2014
  ident: 10.1016/j.ygyno.2016.09.010_bb0125
  article-title: MicroRNAs in cancer: biomarkers, functions and therapy
  publication-title: Trends Mol. Med.
  doi: 10.1016/j.molmed.2014.06.005
– volume: 26
  start-page: 155
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0010
  article-title: Surgical technique of en bloc pelvic resection for advanced ovarian cancer
  publication-title: J. Gynecol. Oncol.
  doi: 10.3802/jgo.2015.26.2.155
– volume: 24
  start-page: 7391
  year: 2005
  ident: 10.1016/j.ygyno.2016.09.010_bb0170
  article-title: AKT signaling in normal and malignant cells
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209100
– volume: 11
  start-page: 441
  year: 2006
  ident: 10.1016/j.ygyno.2016.09.010_bb0120
  article-title: The diverse functions of microRNAs in animal development and disease
  publication-title: Dev. Cell
  doi: 10.1016/j.devcel.2006.09.009
– volume: 25
  start-page: 917
  year: 2007
  ident: 10.1016/j.ygyno.2016.09.010_bb0185
  article-title: PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2007.02.017
– volume: 19
  start-page: 4662
  year: 2013
  ident: 10.1016/j.ygyno.2016.09.010_bb0100
  article-title: microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2
  publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-13-0244
– volume: 14
  start-page: 3319
  year: 2008
  ident: 10.1016/j.ygyno.2016.09.010_bb0110
  article-title: Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-07-4054
– volume: 101
  start-page: 1524
  year: 2014
  ident: 10.1016/j.ygyno.2016.09.010_bb0055
  article-title: Regulatory role of microRNAs in ovarian function
  publication-title: Fertil. Steril.
  doi: 10.1016/j.fertnstert.2014.04.024
– volume: 65
  start-page: 87
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0005
  article-title: Global cancer statistics, 2012
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21262
– volume: 36
  start-page: 1881
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0075
  article-title: MicroRNA-17 promotes normal ovarian cancer cells to cancer stem cells development via suppression of the LKB1-p53-p21/WAF1 pathway
  publication-title: Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine
  doi: 10.1007/s13277-014-2790-3
– volume: 37
  start-page: 620
  year: 2014
  ident: 10.1016/j.ygyno.2016.09.010_bb0145
  article-title: Upregulation of miR-760 and miR-186 is associated with replicative senescence in human lung fibroblast cells
  publication-title: Mol. Cell
  doi: 10.14348/molcells.2014.0157
– volume: 8
  start-page: 51
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0060
  article-title: MicroRNAs in ovarian function and disorders
  publication-title: Journal of Ovarian Research
  doi: 10.1186/s13048-015-0162-2
– volume: 11
  start-page: 3
  issue: Suppl. 1
  year: 2001
  ident: 10.1016/j.ygyno.2016.09.010_bb0020
  article-title: Ovarian cancer screening in the general population: current status
  publication-title: International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society
  doi: 10.1046/j.1525-1438.2001.11(suppl.1)sup1003.x
– volume: 21
  start-page: 3783
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0085
  article-title: PHLPP2 downregulation contributes to lung carcinogenesis following B[a]P/B[a]PDE exposure
  publication-title: Clin. Cancer Res.: An Official Journal of the American Association for Cancer Research
  doi: 10.1158/1078-0432.CCR-14-2829
– volume: 854
  start-page: 419
  year: 2016
  ident: 10.1016/j.ygyno.2016.09.010_bb0155
  article-title: Photoreceptor neuroprotection: regulation of Akt activation through serine/threonine phosphatases, PHLPP and PHLPPL
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-3-319-17121-0_55
– volume: 135
  start-page: 19
  year: 2014
  ident: 10.1016/j.ygyno.2016.09.010_bb0025
  article-title: Impact of obesity on surgical and oncologic outcomes in ovarian cancer
  publication-title: Gynecol. Oncol.
  doi: 10.1016/j.ygyno.2014.07.103
– volume: 35
  start-page: 31
  year: 2016
  ident: 10.1016/j.ygyno.2016.09.010_bb0070
  article-title: MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression
  publication-title: J. Exp. Clin. Cancer Res.: CR.
  doi: 10.1186/s13046-016-0307-1
– volume: 5
  start-page: 8
  year: 2012
  ident: 10.1016/j.ygyno.2016.09.010_bb0050
  article-title: MicroRNAs and ovarian function
  publication-title: Journal of Ovarian Research
  doi: 10.1186/1757-2215-5-8
– volume: 15
  start-page: 687
  year: 2015
  ident: 10.1016/j.ygyno.2016.09.010_bb0195
  article-title: High PHLPP expression is associated with better prognosis in patients with resected lung adenocarcinoma
  publication-title: BMC Cancer
  doi: 10.1186/s12885-015-1711-1
SSID ssj0003012
Score 2.4338017
Snippet Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and...
Abstract Objective Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying...
SourceID pubmed
crossref
elsevier
SourceType Index Database
Enrichment Source
Publisher
StartPage 655
SubjectTerms Blotting, Western
Carcinogenesis - genetics
Cell Line, Tumor
Cell Proliferation - genetics
Down-Regulation
Female
Gene Expression Regulation, Neoplastic
HEK293 Cells
Hematology, Oncology and Palliative Medicine
Humans
In Vitro Techniques
MicroRNAs - genetics
miR-760
Obstetrics and Gynecology
Ovarian cancer
Ovarian Neoplasms - genetics
Ovarian Neoplasms - metabolism
PHLPP2
Phosphoprotein Phosphatases - metabolism
Proliferation
Real-Time Polymerase Chain Reaction
Up-Regulation
Title MiR-760 overexpression promotes proliferation in ovarian cancer by downregulation of PHLPP2 expression
URI https://www.clinicalkey.com/#!/content/1-s2.0-S009082581631410X
https://www.clinicalkey.es/playcontent/1-s2.0-S009082581631410X
https://dx.doi.org/10.1016/j.ygyno.2016.09.010
https://www.ncbi.nlm.nih.gov/pubmed/27726922
Volume 143
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dT9swELcQk6a9oI0x6BjID3tcRmIndvxYVaBCKaoQiL5Z8RcqQqFqi0Rf-Nvnc5wytKlIPOXLdpLz5Xyn_H53CP0kqeJUVyaxzPoAxZUuqQS1CVPBGyZUhBpLwwvWv87PxsV4A_VaLgzAKqPtb2x6sNbxzFGU5tF0MgGOL5TrLkrvUQBYcQwM9pyDlv9-foF5eAVuMoYHynRRtpmHAsZrebusgQGYsZDsFGi0a1env5aek89oK_qMuNs81he0Yett9HEY_4p_RW44uUw4SzHAMe1ThLbWeBqgdnYOO_cAYQmzgCe1b-hD5KrGGuZ8htUSGx-Nz5q69NDmweFR_3w0IvhlvB10fXJ81esnsX5ConPGFok2lfIrFFE8FUYYbZmghldGA520dIZTZRkXTlW6ctRfJLRgxmS6zKyP2hz9hjbrh9ruIey4LY2PPTJe5XmutKKuEN73IJnNylJkHURauUkdk4tDjYt72aLI7mQQtgRhy1RIL-wO-rXqNG1ya6xvnrcTIlvaqDd00tv-9d34_7rZefxY5zKTcyJT-Y9CdRBb9Xylk2_fcrfRl9VrER_EMEHI9_cOuY8-wVEDpPmBNhezR3vg3aGFOgz6fog-dE8H_QvYDi5vBn8Ah9YLxA
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIkEviGdZnj7AjdDESez4wAEB1ZbuVivUSnsz8ataVKWrzVawF_4Uf5Cx42xBoEVC6i1KPI7yeTyeUb6ZAXhBU8VzXZvEMosBiqtcUovcJkwFb5jmIvRYGh-x4UnxcVpOt-BHnwvjaZXR9nc2PVjreGcvork3n818jq9v111W6FF4suI0MisP7eorxm3tm4P3uMgvKd3_cPxumMTWAokuGFsm2tQKjTdVPBVGGG2ZyA2vjfaZlpUzPFeWceFUrWuX40Oal8yYTFeZxYDG5TjvNbheoLnwbRNef7_kleCO6UqUhxztsupLHQVS2ep01fiUw4yF6qo-b3fjcfjLWbd_G25FJ5W87XC4A1u2uQs3xvE3_D1w49mnhLOUeP6n_Ra5tA2ZB26fbf3FmefMhGUnswYHYkxeN0R7JVsQtSIGw_-FPY3dw8i5I5PhaDKh5HK--3ByJag-gO3mvLEPgThuK4PBTsbroiiUVrkrBTo7NLNZVYlsALTHTepYzdw31TiTPW3tiwxgSw-2TIVEsAfwai0074p5bB5e9Asi-zxVtKwSD5vNYvxvYraN1qGVmWypTOUfGjwAtpb8bRP8-5W7nb6sP4ti1MQEpY_-d8rncHN4PB7J0cHR4WPY8U86Fs8T2F4uLuxT9MWW6lnQfQKfr3qz_QSHS0cr
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MiR-760+overexpression+promotes+proliferation+in+ovarian+cancer+by+downregulation+of+PHLPP2+expression&rft.jtitle=Gynecologic+oncology&rft.au=Liao%2C+Yanbin&rft.au=Deng%2C+Yalan&rft.au=Liu%2C+Jun&rft.au=Ye%2C+Zhanying&rft.date=2016-12-01&rft.issn=0090-8258&rft_id=info:doi/10.1016%2Fj.ygyno.2016.09.010&rft.externalDBID=ECK1-s2.0-S009082581631410X&rft.externalDocID=1_s2_0_S009082581631410X
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon